Covid 19 Clinical Trials

Acute and chronic inflammatory eye diseases are difficult to diagnose and maintain quiescent with therapy. Proposed study is aimed to find on the one hand, novel factors for recurrence of the disease or remission of inflammation and evaluation of the impact of lifestyle and known factors on the other. Each patient is treated in accordance to the best of medical knowledge and guidelines for each disease. This prospective cohort study will enroll uveitic patients to the steroid only group (SG), combined (steroid and adjuvant drug) group (CG) or bilogic therapy group (BTG). At baseline, patient data are recorded using patient-reported outcome measures and clinical assessments (ophthalomology) on disease activity (clinical scales), quality of life, and lifestyle together with registry data on comorbidity and medication. During follow-up evaluation of a successful treatment outcome response will be based on clinical scales and most frequently used primary endpoints; the major outcome of the analyses will be to detect differences in treatment outcome between patients in different treatment group.

NCT04193020 Uveitis Other: Surveillance card

MeSH:Uveitis

HPO:Uveitis

Primary Outcomes

Description: Total number of treatment success in each group

Measure: Treatment success

Time: 1 year

Description: Time to the next recurrence after the treatment regimen introduction

Measure: Recurrence time

Time: 10 years

Description: Time and cause of severe visual loss

Measure: Severe visual loss

Time: 10 years

Secondary Outcomes

Description: Visual Acuity will be performed with ETDRS charts different for right and left eye

Measure: ETDRS Visual Acuity

Time: 10 years

Description: At each visit anterior chamber will be examined to assess anterior chamber cells (1mm x 1mm slit beam in height and width, when thrown at an angle of 45-60°). The recorded number of cells will be used to determine the grade according to the SUN criteria.

Measure: The SUN working group grading system for anterior chamber cells

Time: 10 years

Description: At each visit anterior chamber will be examined to assess anterior chamber flare (1mm x 1mm slit beam in height and width, when thrown at an angle of 45-60°). The observed changes will be used to determine the grade according to the SUN criteria.

Measure: The SUN working group grading system for anterior chamber flare

Time: 10 years

Description: Using AREDS system for classifying cataracts from photographs: AREDS Report No. 4 the lens opacity will be graded.

Measure: AREDS 2008 Clinical Lens Opacity Grading Procedure

Time: 10 years

Description: At each visit vitreous will be examined to assess vitreous cells (1mm x 3mm slit beam in anterior vitreous). The recorded number of cells will be used to determine the grade according to the NIH criteria.

Measure: NIH grading system for vitreous cells

Time: 10 years

Description: At each visit vitreous will be examined to assess vitreous haze. The recorded of clarity of posterior pole funduscopy will be used to determine the grade according to the NIH criteria.

Measure: NIH grading system for vitreous haze

Time: 10 years

Description: OCT EDI recordings processed with developed by researchers methodology for image processing.

Measure: Submacular choroidal thickness

Time: 10 years

Other Outcomes

Description: PCR-positive result of COVID-19 specific testing, no treatment required

Measure: COVID-19 confirmed infection asymptomatic patient

Time: 1 year

Description: PCR-positive result of COVID-19 specific testing, patient require treatment. The mode of treatment will be recorded into several groups: 1) antibiotics, 2) antivirals, 3) biologic treatment, 4) immunoglobulins, 5) steroids

Measure: COVID-19 confirmed infection

Time: 1 year

Description: COVID-19 related acute respiratory distress syndrome (ARDS). Situation in which patients need any of described below: 1) supportive oxygen therapy, 2) non-invasive ventilation, 3) invasive/ mechanical ventilation, 4) use of ECMO, 5) admission to intensive care unit, 6) dialysis

CovidResearchTrials by Shray Alag

Covid 19 Research using Clinical Trials (Home Page)

Surveillance cardWiki

Developed by Shray Alag

Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation

Correlated Drug Terms (0)

Correlated MeSH Terms (1)

Correlated HPO Terms (1)

Clinical Trials

1 Impact of Lifestyle and Treatment on the Recurrency and Severity of Acute and Chronic Inflamatory Eye Diseases: Protocol on Prospective Cohort Study

NCT04193020 Uveitis Other: Surveillance card

MeSH:Uveitis

HPO:Uveitis

Primary Outcomes

Secondary Outcomes

Other Outcomes

Related HPO nodes (Using clinical trials)

HP:0000554: Uveitis

Genes 46

Protein Mutations 0

SNP 0